Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972056 · ClinicalTrials.gov registry record · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
A Phase 4 study of Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,335
- Enrollment target
- 18
- Study locations
NCT06972056: Recruiting Phase 4 study of Migraine, sponsored by Mayo Clinic.
NCT06972056 is a Phase 4 study of Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,335 participants, above the 345-participant average among 102 other Migraine trials with a reported enrollment target (287% higher). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972056, a Phase 4 study of Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,335 participants
- Enrollment target
- 18
- Study locations
Study Summary
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.
Primary Outcome
This study will use a "treatment responder" primary endpoint that will investigate medication superiority using a combination of headache frequency reduction and medication persistence. To achieve this, a binary endpoint of treatment response will be used that combines effectiveness and medication persistence at the individual level, with success defined as: 1. Completing the first 12 weeks of the study on the assigned medication without discontinuation due to any reason, AND 2. Having a 50% or
Conditions Studied
Interventions
- DRUG Atogepant 60 mg
- DRUG Propranolol 160 mg
- DRUG Topiramate 100 mg
Study Locations (18)
Arizona
- Northern Arizona Healthcare - Flagstaff
- Mayo Clinic Arizona - Phoenix
California
- USC Keck - Los Angeles
- Clinical Research Institute - Los Angeles
Florida
- Mayo Clinic Florida - Jacksonville
- Apple Med Research - Miami
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University St Louis - St Louis
Nevada
- Advanced Research Institute Reno - Reno
New Jersey
- JFK Neuroscience Institute - Edison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,335 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 4 |
What NCT06972056 shows while recruiting
NCT06972056 is an interventional study that assigns participants to a tested intervention. Its 1,335 participants enrollment target places it among the larger protocols in the corpus, above the 345-participant average among 102 other Migraine trials with a reported enrollment target (287% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Atogepant 60 mg is the first listed.
NCT06972056 lists 18 locations in 15 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06972056 about?
NCT06972056 is a clinical study titled "Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study". This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerab...
What is the current status of trial NCT06972056?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,335 participants. The study started on 2025-07-09. Estimated completion is 2029-12-01.
What conditions does trial NCT06972056 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06972056?
The interventions under investigation include: Atogepant 60 mg (DRUG), Propranolol 160 mg (DRUG), Topiramate 100 mg (DRUG).
Who is sponsoring clinical trial NCT06972056?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972056 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06972056's enrollment target sits among peer trials
1,335 8th of 102 higher than 95 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI